Simplify Healthcare Captures 30% Medicare Advantage Market Share
Platform achieves 30% market dominance in Medicare Advantage bid submissions.
Platform achieves 30% market dominance in Medicare Advantage bid submissions.
The National Institute for Health and Care Excellence (NICE) has approved linzagolix combined with hormonal add-back therapy for endometriosis treatment within the NHS, expanding therapeutic options for an estimated 1.5 million women in the UK affected by this chronic condition. Clinical trials have substantiated that linzagolix effectively reduces both dysmenorrhea and non-menstrual pelvic pain in … Read more
A validated capacity assessment tool designed to strengthen orthopedic surgery capabilities in low- and middle-income countries (LMICs) has demonstrated excellent reliability and practical utility in pilot testing, addressing a critical healthcare disparity that affects millions globally. The Capacity Assessment Tool for Orthopedic Surgery (CAT-os) provides systematic evaluation frameworks for surgical outreach programs targeting regions where … Read more
Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the … Read more